SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Phase 2
Completed
- Conditions
- Dengue FeverDengue VirusDengue DiseasesDengue Hemorrhagic Fever
- Interventions
- Biological: NaCl + influenza virus or hepatitis A vaccineBiological: CYD Dengue vaccine
- First Posted Date
- 2009-04-14
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1198
- Registration Number
- NCT00880893
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Phase 2
Completed
- Conditions
- Dengue DiseaseDengue FeverDengue VirusDengue Hemorrhagic Fever
- Interventions
- Biological: CYD dengue vaccine serotypes (1, 2, 3, 4).Biological: Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 180
- Registration Number
- NCT00875524
- Locations
- 🇻🇳
Sanofi Pasteur Investigational Site, Long Xuyên, An Giang Province, Vietnam
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
Phase 1
Completed
- Conditions
- Meningococcal InfectionsMeningococcal Meningitis
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 216
- Registration Number
- NCT00874549
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
Completed
- Conditions
- MeningitisMeningococcal Infections
- Interventions
- Biological: Menomune®Biological: Menactra®
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 763
- Registration Number
- NCT00862277
Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus vaccine (2004-2005 Formulation)
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 394
- Registration Number
- NCT00858468
Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Completed
- Conditions
- Haemophilus InfectionsPertussisTetanusPolioDiphtheria
- Interventions
- Biological: DTaP-IPV/Hib
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 20830
- Registration Number
- NCT00855855
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
Phase 4
Completed
- Conditions
- MeningitisMeningococcal Infections
- Interventions
- Biological: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 170
- Registration Number
- NCT00850603
Efficacy and Safety of Dengue Vaccine in Healthy Children
Phase 2
Completed
- Conditions
- Dengue VirusDengue FeverDengue Hemorrhagic FeverDengue Diseases
- Interventions
- Biological: CYD Dengue VaccineBiological: Inactivated rabies virus vaccineBiological: Placebo
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 4002
- Registration Number
- NCT00842530
- Locations
- 🇹🇭
Sanofi Pasteur Investigational Site, Bangkok, Thailand
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus vaccine
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 121
- Registration Number
- NCT00835926
Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza virus vaccine (Pediatric formulation)
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 33
- Registration Number
- NCT00836953
© Copyright 2025. All Rights Reserved by MedPath